Floatz logo

in1011-n17 hcl

Osteoarthritis

iN Therapeutics Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Osteoarthritis cohort.

Asset / SponsorPhaseRating
Naltrexone
Brigham and Women's Hospital
Phase 4BBB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BBB
FENTANYL
Janssen Pharmaceutica
Phase 4BBB
Oxycodone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
Duloxetine
The Catholic University of Korea
Phase 4BBB

View all 48 →

Same molecule, other indications

in1011-n17 hcl is also rated in:

postherpetic neuralgiaDormant
CC
Indicative ·
43 / 100
View asset →
Dorsal Root GanglionDormant
CC
Indicative ·
43 / 100
View asset →
Nav 1.7Dormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →